Ir para o conteúdo principal

Grafa News and Videos — Page 99

Destaques de Grafa

Grafa
Health

Pharming reports positive Phase II results for leniolisib in rare immune disorders

Pharming Group (NASDAQ:PHAR) announced positive topline results from a Phase II study evaluating leniolisib in patients with genetically identifiable primary immunodeficiencies (PIDs) associated with immune dysregulation caused by PI3Kδ signaling abnormalities.

Leia mais: Pharming reports positive Phase II results for leniolisib in rare immune disorders

GARANTA JÁ SEU GRAFA EDGE

Vamos ativar um teste de 30 dias do Edge como presente de boas-vindas